These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 31266627)

  • 1. HBV/HDV Coinfection: A Challenge for Therapeutics.
    Koh C; Da BL; Glenn JS
    Clin Liver Dis; 2019 Aug; 23(3):557-572. PubMed ID: 31266627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology, Natural History, and Treatment of Hepatitis Delta Virus Infection in HIV/Hepatitis B Virus Coinfection.
    Ferrante ND; Lo Re V
    Curr HIV/AIDS Rep; 2020 Aug; 17(4):405-414. PubMed ID: 32607773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis D: A Review.
    Negro F; Lok AS
    JAMA; 2023 Dec; 330(24):2376-2387. PubMed ID: 37943548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond Pegylated Interferon-Alpha: New Treatments for Hepatitis Delta.
    Deterding K; Wedemeyer H
    AIDS Rev; 2019; 21(3):126-134. PubMed ID: 31532397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging concepts for the treatment of hepatitis delta.
    Elazar M; Glenn JS
    Curr Opin Virol; 2017 Jun; 24():55-59. PubMed ID: 28475945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of delta hepatitis.
    Gunsar F
    Expert Rev Anti Infect Ther; 2013 May; 11(5):489-98. PubMed ID: 23627855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current management of delta hepatitis.
    Rizzetto M
    Liver Int; 2013 Feb; 33 Suppl 1():195-7. PubMed ID: 23286865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139-Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection.
    Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Anderson M; Gersch J; Holzmayer V; Elsner C; Krawczyk A; Kuhns MC; Cloherty G; Dittmer U; Vaillant A
    Hepatol Commun; 2021 Feb; 5(2):189-202. PubMed ID: 33553968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic hepatitis delta: A state-of-the-art review and new therapies.
    Gilman C; Heller T; Koh C
    World J Gastroenterol; 2019 Aug; 25(32):4580-4597. PubMed ID: 31528088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diagnosis and treatment of chronic hepatitis B and D. Hungarian national consensus guideline].
    Horváth G; Hunyady B; Gervain J; Lengyel G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I
    Orv Hetil; 2014 Mar; 155 Suppl():25-36. PubMed ID: 24631887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
    Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy.
    Lutterkort GL; Wranke A; Hengst J; Yurdaydin C; Stift J; Bremer B; Hardtke S; Keskin O; Idilman R; Manns MP; Dienes HP; Falk C; Wedemeyer H; Heidrich B
    J Viral Hepat; 2018 Nov; 25(11):1384-1394. PubMed ID: 29888837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigational drugs in development for Hepatitis D.
    Rizzetto M
    Expert Opin Investig Drugs; 2017 Sep; 26(9):999-1005. PubMed ID: 28730878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of hepatitis D: an unmet medical need.
    Caviglia GP; Rizzetto M
    Clin Microbiol Infect; 2020 Jul; 26(7):824-827. PubMed ID: 32120043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options.
    Lempp FA; Ni Y; Urban S
    Nat Rev Gastroenterol Hepatol; 2016 Oct; 13(10):580-9. PubMed ID: 27534692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment.
    Grabowski J; Yurdaydìn C; Zachou K; Buggisch P; Hofmann WP; Jaroszewicz J; Schlaphoff V; Manns MP; Cornberg M; Wedemeyer H;
    Liver Int; 2011 Oct; 31(9):1395-405. PubMed ID: 21762356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bulevirtide: First Approval.
    Kang C; Syed YY
    Drugs; 2020 Oct; 80(15):1601-1605. PubMed ID: 32926353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling.
    Guedj J; Rotman Y; Cotler SJ; Koh C; Schmid P; Albrecht J; Haynes-Williams V; Liang TJ; Hoofnagle JH; Heller T; Dahari H
    Hepatology; 2014 Dec; 60(6):1902-10. PubMed ID: 25098971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New treatment options for delta virus: Is a cure in sight?
    Yurdaydin C
    J Viral Hepat; 2019 Jun; 26(6):618-626. PubMed ID: 30771261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon alpha induces a stronger antiviral effect than interferon lambda in HBV/HDV infected humanized mice.
    Duehren S; Uchida T; Tsuge M; Hiraga N; Uprichard SL; Etzion O; Glenn J; Koh C; Heller T; Cotler SJ; Oka S; Chayama K; Dahari H
    Virus Res; 2024 Nov; 349():199451. PubMed ID: 39168375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.